MedTrace Logo

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

NCT01363843 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-06-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery. Patients have recently been diagnosed with rectal cancer, and the doctors have recommended neo-adjuvant chemo treatment to try to shrink the cancer before removing it.

Conditions

Interventions

DRUG

FOLFOX6

FOLFOX6

RADIATION

RT with concurrent chemotherapy

IMRT 50.4Gy with chemotherapy

PROCEDURE

Surgery

Sponsors & Collaborators

  • Memorial Hospital of Rhode Island

    collaborator OTHER

  • Rhode Island Hospital

    collaborator OTHER

  • The Miriam Hospital

    collaborator OTHER

  • William Sikov MD

    lead OTHER

Principal Investigators

  • William Sikov, MD · Brown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363843 on ClinicalTrials.gov